search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Sandostatin therapy in sarcoidosis


- candidate number18206
- NTR NumberNTR4655
- ISRCTNISRCTN no longer applicable
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR26-jun-2014
- Secondary IDsMACS2757 Novartis
- Public TitleSandostatin therapy in sarcoidosis
- Scientific TitleSandostatin therapy in sarcoidosis
- ACRONYMSST in SA
- hypothesisSarcoidosis (SA) is a rare systemic disease that is characterized by the formation of granulomas. It can affect any organ in the body. Somatostatin is a peptide hormone that regulates neuroendocrine processes but it also is an intersystem signalling molecule on the immune system and is implicated in the pathogenesis of SA. Sandostatin (SST), octreotide is the stable and synthetic analogue of the natural somatostatin. Octreotide has an inhibitory effect of the immune system. Affected locations in SA show octreotide uptake on SRS. As corticosteroids, with all the additional disadvantages, are first-line treatment in sarcoidosis, SST is studied as an alternative treatment for SA.
- Healt Condition(s) or Problem(s) studiedSarcoidosis
- Inclusion criteria1. Age above 18 years with obtained written consent
2. Have biopsy-proven symptomatic, stable, chronic sarcoidosis for minimal three years.
3. Have a positive SRS
4. Involvement of skin, joint, lymph nodes or lung. Patients with pulmonary involvement have a diffusing capacity between 60 and 75 percent.
- Exclusion criteria1. Corticosteroid use up to three months prior of trial
2. Chronic renal failure defined as a GFR below 50%
3. Liver disease
4. Have an indication for intensifying immunosuppressive therapy; threatening organ damage
5. Have failed on earlier anti TNF-alfa therapy
6. Have an underlying cardiac disease
- mec approval receivedyes
- multicenter trialno
- randomisedno
- group[default]
- TypeSingle arm
- Studytypeintervention
- planned startdate 1-jul-2014
- planned closingdate1-jul-2016
- Target number of participants20
- InterventionsPatients will receive 20 mg of sandostatin injection intramuscular IM every month for six months.
- Primary outcomeThe main endpoint is the change in uptake on somatostatin receptor scan.
- Secondary outcomeThe secondary endpoint is the composite clinical score using the following parameters: blood test (ESR, CRP, full blood count, lysozyme, ACE, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, sIL-2R), quality of life (RAND-36) and when applicable lung function test (FVC, DLCO) and skin evaluation.
- TimepointsDuration of intervention is six months. Primary endpoint (somatostatin receptor scan) after nine months after initiation therapy. Total folluw up is 12 months.
- Trial web siteN/A
- statusopen: patient inclusion
- CONTACT FOR PUBLIC QUERIESMD. PhD. P.L.A. Daele, van
- CONTACT for SCIENTIFIC QUERIESMD. PhD. S.J.C.M.M. Neggers
- Sponsor/Initiator Erasmus Medical Center, Department of Internal Medicine
- Funding
(Source(s) of Monetary or Material Support)
Novartis
- PublicationsN/A
- Brief summaryDesign:nonrandomized, open label, proof of principal investigator initiated trial.

Subjects:patients with chronic, symptomatic and stable sarcoidosis that show inflammatory activity on somatostatin receptor scan and previously received treatment with corticosteroids.

Study medication:Monthly injections with sandostatin for six months.

Objective: To evaluate efficacy of sandostatin in a subset of patients that are refractory/intolerant to corticosteroid therapy.

Primary endpoint:change in uptake on somatostatin receptor scan.

Secondary enpoints: bloodtests, quality of life score, pulmonary function and skin evaluation.
- Main changes (audit trail)
- RECORD26-jun-2014 - 6-aug-2014


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl